EMA/PE/0000232896
EMA/PE/0000232896
EMA/PE/0000232896
EMEA-000976-PIP01-10
Opinion/decision on a Paediatric investigation plan (PIP): Zeposia, Ozanimod (hydrochloride), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0131/2022
Human medicines European public assessment report (EPAR): Celsentri, maraviroc, Date of authorisation: 18/09/2007, Revision: 32, Status: Authorised
Agenda of the CVMP meeting 13-15 January 2026
Pharmacovigilance Risk Assessment Committee (PRAC): 12 - 15 January 2026, European Medicines Agency, Amsterdam, the Netherlands, from 12 January 2026 to 15 January 2026
Agenda of the PRAC meeting 12 - 15 January 2026
Q&A clinic on Substance, Organisation, Referentials Management Services, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 15 December 2025, 11:00 (CET) to 15 December 2025, 12:00 (CET)
Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 December 2025, 11:00 (CET) to 18 December 2025, 12:00 (CET)
Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 December 2025, 14:00 (CET) to 18 December 2025, 15:00 (CET)